Compare Starbucks Corp (SBUX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs Summit Therapeutics Inc — how do they compare? Starbucks Corp trades at $104.35 (market cap $119.45B), while Summit Therapeutics Inc trades at $14.58 (market cap $10.48B). The key difference: Starbucks Corp is far larger — about 11.4× Summit Therapeutics Inc's market cap, and Starbucks Corp pays a 2.37% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SBUX | SMMT | |
|---|---|---|
Market Cap | $119.45B | $10.48B |
Volume | 7,493,833 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $108.37 | $29.32 |
52-Week Low | $78.46 | $13.05 |
Enterprise Value | $142.14B | $9.90B |
Dividend Yield | 2.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $104.45, down 0.99% today, near its 52-week high with a bullish technical trend. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $37.18B in 2025, though net income fell to $1.86B, reflecting margin pressures. Analysts maintain a buy consensus with a $108.86 target, citing turnaround progress and cost-saving initiatives, including AI-driven software reductions.
SBUX's outlook is cautiously optimistic, supported by traffic growth and raised 2026 guidance, but profitability remains a concern with a high P/E of 80.01. Key risks include intense competition from Luckin Coffee and macroeconomic sensitivity. Institutional sentiment is positive, with 47% buy ratings, though investors should monitor execution on margin recovery and cost efficiency targets.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
